Drug Trial Radar · NCT01799993
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Last checked: Nov 19, 2026Latest source record: Jul 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
725
Actual
Start
Apr 13, 2013
Primary completion
Apr 7, 2017
Study completion Apr 7, 2017
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Nektar Therapeutics
- First posted
- Feb 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and more effective than placebo (aerosolized normal saline) administered as an aerosol by the PDDS Clinical every 12 hours, in intubated and mechanically-ventilated patients with Gram-negative Pneumonia. The secondary endpoint objectives are to evaluate the superiority of aerosolized BAY 41-6551 versus aerosolized placebo in pneumonia-related mortality, the Early Clinical Response at Day 10, the days on ventilation, and the days in the intensive care unit (ICU).
Conditions
- Pneumonia, Bacterial
Interventions
Amikacin Inhalation Solution (BAY41-6551)Drug
400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
Aerosolized PlaceboDrug
Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Surviving Through LFU VisitTime frame: Up to 28-32 days after start of study treatment
Locations
65 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Phoenix, Arizona
Site not named
Danbury, Connecticut
Site not named
Hartford, Connecticut
Site not named
Newark, Delaware
Site not named
Hollywood, Florida
Site not named
Miami, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Springfield, Illinois
Site not named
Muncie, Indiana
Site not named
Iowa City, Iowa
Site not named
Hazard, Kentucky
Site not named
Kalamazoo, Michigan
Site not named
Springfield, Missouri
Site not named
St Louis, Missouri
Site not named
Butte, Montana
Site not named
Las Vegas, Nevada
Site not named
Brooklyn, New York
Site not named
Mineola, New York
Site not named
New York, New York
Site not named
New York, New York
Site not named
Asheville, North Carolina
Site not named
Greensboro, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Youngstown, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Charleston, South Carolina
Site not named
Wollongong, Australia
Site not named
Blacktown, New South Wales, Australia
Site not named
Clayton, Victoria, Australia
Site not named
Belo Horizonte, Minas Gerais, Brazil
Site not named
Campinas, São Paulo, Brazil
Site not named
São José do Rio Preto, São Paulo, Brazil
Site not named
Québec, Canada
Site not named
Kingston, Ontario, Canada
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.